Postresection Routine Surveillance with CT Instead of Chest X-Ray Does Not Improve Survival in Early-Stage Lung Cancer
Toronto, Canada—Survival is not improved with routine surveillance using computed tomography (CT) versus chest x-ray in patients who have undergone resection for stage I non–small-cell lung cancer (NSCLC), according to the results of a new analysis presented at the 2014 American Association for Thoracic Surgery meeting.
Chicago, IL— Necitumumab, a human immunoglobulin G1 anti-EGFR monoclonal antibody, added to standard chemotherapy significantly improved survival compared with chemotherapy alone as first-line treatment of patients with stage IV non–small-cell lung cancer (NSCLC) of squamous histology.
Chicago, IL—When added to chemotherapy (ie, docetaxel), the new monoclonal antibody ramucirumab improved overall survival (OS) compared with chemotherapy alone in patients with stage IV non–small-cell lung cancer (NSCLC), according to phase 3 trial results presented at the 2014 American Society of Clinical Oncology meeting.
Hollywood, FL—Driver mutations, most frequently KRAS and EGFR, account for approximately 50% of non–small-cell lung cancer (NSCLC), and this recognition is shifting the NSCLC treatment paradigm toward targeted therapy when possible, said Leora Horn, MD, MSc, Assistant Professor of Medicine, Division of Hematology/ Oncology, Vanderbilt University, Nashville, TN, at the 2014 National Comprehensive Cancer Network Conference.
The US Preventive Services Task Force (USPSTF) is recommending that individuals aged >55 years who have a history of heavy smoking be screened annually for lung cancer.
If adopted, this initiative will bring an estimated 14% reduction in lung cancer–related mortality as a result of early disease detection, according to the USPSTF position paper, which was recently published online (Moyer VA. Ann Intern Med. 2014 January 14. Epub ahead of print).
Boston, MA—Patients with ALK-positive non–small-cell lung cancer (NSCLC) continued with crizotinib therapy more than twice as long when drug-resistant lesions were managed with local ablation, as shown by the results of a small clinical trial presented at the 2012 American Society for Radiation Oncology meeting.
Page 2 of 2
Results 11 - 16 of 16
Results 11 - 16 of 16